Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors⦠read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
$13.74
Price-0.65%
-$0.09
$96.496m
Small
19.6x
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$188.667m
-
1y CAGR-
3y CAGR-
5y CAGR$5.795m
-
1y CAGR-
3y CAGR-
5y CAGR-$0.43
-
1y CAGR-
3y CAGR-
5y CAGR-$35.041m
$36.902m
Assets$71.943m
Liabilities$15.426m
Debt41.8%
1.1x
Debt to EBITDA-$64.006m
-
1y CAGR-
3y CAGR-
5y CAGR